190 related articles for article (PubMed ID: 24708616)
21. A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage.
Chen X; Bosques L; Sung P; Kupfer GM
Oncogene; 2016 Jan; 35(1):22-34. PubMed ID: 25893307
[TBL] [Abstract][Full Text] [Related]
22. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
23. BRIP1 variations analysis reveals their relative importance as genetic susceptibility factor for cervical cancer.
Ma XD; Cai GQ; Zou W; Huang YH; Zhang JR; Wang DT; Chen BL
Biochem Biophys Res Commun; 2013 Apr; 433(2):232-6. PubMed ID: 23473757
[TBL] [Abstract][Full Text] [Related]
24. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Wachters FM; Wong LS; Timens W; Kampinga HH; Groen HJ
Lung Cancer; 2005 Nov; 50(2):211-9. PubMed ID: 16169122
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathogenesis of fanconi anemia.
Taniguchi T; Dandrea AD
Int J Hematol; 2002 Feb; 75(2):123-8. PubMed ID: 11939257
[TBL] [Abstract][Full Text] [Related]
27. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
28. Deficient regulation of DNA double-strand break repair in Fanconi anemia fibroblasts.
Donahue SL; Lundberg R; Saplis R; Campbell C
J Biol Chem; 2003 Aug; 278(32):29487-95. PubMed ID: 12748186
[TBL] [Abstract][Full Text] [Related]
29. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
30. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
32. The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Wang XJ; Xiong Y; Ma ZB; Xia JC; Li YF
Chin J Cancer; 2016 Jun; 35(1):54. PubMed ID: 27311570
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
van der Groep P; Hoelzel M; Buerger H; Joenje H; de Winter JP; van Diest PJ
Breast Cancer Res Treat; 2008 Jan; 107(1):41-7. PubMed ID: 17333336
[TBL] [Abstract][Full Text] [Related]
34. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Yamashita T; Nakahata T
Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
36. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
[TBL] [Abstract][Full Text] [Related]
37. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
Shen X; Do H; Li Y; Chung WH; Tomasz M; de Winter JP; Xia B; Elledge SJ; Wang W; Li L
Mol Cell; 2009 Sep; 35(5):716-23. PubMed ID: 19748364
[TBL] [Abstract][Full Text] [Related]
38. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
39. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability.
Bogliolo M; Lyakhovich A; Callén E; Castellà M; Cappelli E; Ramírez MJ; Creus A; Marcos R; Kalb R; Neveling K; Schindler D; Surrallés J
EMBO J; 2007 Mar; 26(5):1340-51. PubMed ID: 17304220
[TBL] [Abstract][Full Text] [Related]
40. CtIP mediates replication fork recovery in a FANCD2-regulated manner.
Yeo JE; Lee EH; Hendrickson EA; Sobeck A
Hum Mol Genet; 2014 Jul; 23(14):3695-705. PubMed ID: 24556218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
